Redbiotec and the research group of Prof. William J. Britt, MD announce a collaboration to study the contribution of complex antigens to protective immunity against Cytomegalovirus (CMV). The goal of the study is to gain insights into the correlates of protection.

Redbiotec will provide proprietary CMV antigens to be tested in sera from a target patient population, an important milestone towards validation of Redbiotec’s CMV vaccine candidates. The study is a continuation of an ongoing collaboration with Prof. Britt.